These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38936417)

  • 1. Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review.
    Giuffrida AC; Siboni SM; Baronciani L; Poli G; Gandini G; Peyvandi F
    Semin Thromb Hemost; 2024 Jun; ():. PubMed ID: 38936417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
    Shanmukhaiah C; Jijina F; Kannan S; Pai NG; Kulkarni B; Khuba SV; Shaikh M; Joshi A; Phatale R; Apte S
    Haemophilia; 2022 Mar; 28(2):286-291. PubMed ID: 35014121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies.
    van der Zwet K; van Galen KPM; Evers ACC; Fischer K; Schutgens REG; van Vulpen LFD
    Res Pract Thromb Haemost; 2024 Mar; 8(3):102399. PubMed ID: 38689620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.
    Yaoi H; Shida Y; Ogiwara K; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2022 Sep; 28(5):694-701. PubMed ID: 35478475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of emicizumab prophylaxis in severe von Willebrand disease.
    Barg AA; Avishai E; Budnik I; Brutman TB; Tamarin I; Dardik R; Bashari D; Misgav M; Lubetsky A; Lalezari S; Livnat T; Kenet G
    Blood Cells Mol Dis; 2021 Mar; 87():102530. PubMed ID: 33341070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
    Thomas VM; Abou-Ismail MY; Lim MY
    Haemophilia; 2022 Jan; 28(1):4-17. PubMed ID: 34820989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease.
    LeMaistre FI; Chiang E; Streiff MB; Yui JC
    Blood Coagul Fibrinolysis; 2024 Jun; 35(4):206-208. PubMed ID: 38625829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
    Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
    J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting von Willebrand disease: the current status and future directions of management therapies.
    Franchini M; Focosi D
    Expert Rev Hematol; 2023; 16(11):871-878. PubMed ID: 37800892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Desensitization of a Patient with Possible IgE-Mediated Anaphylactic Reaction to FVIII/VWF Concentrate.
    Beken B; Celik V; Gokmirza Ozdemir P; Eren T; Yazicioglu M
    Pediatr Allergy Immunol Pulmonol; 2019 Jun; 32(2):81-84. PubMed ID: 31508262
    [No Abstract]   [Full Text] [Related]  

  • 19. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
    Favaloro EJ; Mohammed S; Vong R; Pasalic L
    Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.